Clinical Trials Logo

Filter by:
NCT ID: NCT02285062 Completed - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

ROBUST
Start date: February 17, 2015
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.

NCT ID: NCT02283762 Completed - Clinical trials for Scleroderma, Systemic

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Start date: January 15, 2015
Phase: Phase 2
Study type: Interventional

To investigate if Riociguat is effective in the treatment of systemic sclerosis

NCT ID: NCT02278263 Completed - Osteoarthritis Clinical Trials

Tranexamic Acid in Knee Joint Surgery

TRACKS
Start date: December 2014
Phase: Phase 4
Study type: Interventional

Total knee joint replacement surgery can lead to significant blood loss, which can affect recovery after surgery. Tranexamic acid (TXA) is a medication which stops the breakdown of blood clots and therefore prevents blood loss. The optimal use of TXA remains a point of debate. Growing interest in the topical application of TXA (directly into the surgical wound) has been suggested as an alternative way of administering TXA, and may demonstrate similar effectiveness as when it is given intravenously. Therefore, this multicentred, randomized controlled trial, aims to investigate the safety and effectiveness of both topical and intravenous administrations of TXA in total knee joint surgery. The investigators predict that both routes of administration will demonstrate similar results when compared to placebo.

NCT ID: NCT02278068 Completed - Diabetes Clinical Trials

COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy

Start date: October 2014
Phase: N/A
Study type: Interventional

The purpose of this research study is to collect information about a new treatment for Type 2 Diabetes Mellitus (T2DM), using a medical device called the Metabolic Neuromodulation System which is intended to help regulate blood glucose levels in patients whose (T2DM) is not well controlled despite treatment with multiple medications. The medical device delivers low-level radiofrequency energy through the wall of the blood vessel to the liver to disrupt the nerves that lead to the liver. Previous research has shown that disrupting these nerves may lead to a lowering of blood sugar levels.

NCT ID: NCT02275117 Completed - Migraine Disorders Clinical Trials

A Multicenter Assessment of ALD403 in Chronic Migraine

Start date: October 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.

NCT ID: NCT02271529 Completed - Clinical trials for Peripheral Vascular Disease

Zilver PTX Delivery System

Start date: September 2014
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the performance of the Zilver PTX stent thumbwheel delivery system.

NCT ID: NCT02264990 Completed - Clinical trials for Non-squamous Non-small Cell Lung Cancer

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Start date: September 30, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.

NCT ID: NCT02264574 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Start date: October 6, 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of ibrutinib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of progression free survival (PFS). Efficacy will be evaluated according to 2008 International Workshop for Chronic Lymphocytic Leukemia (IWCLL) criteria with the modification for treatment-related lymphocytosis, in subjects with treatment-naive CLL or SLL.

NCT ID: NCT02260986 Completed - Atopic Dermatitis Clinical Trials

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

CHRONOS
Start date: September 2014
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.

NCT ID: NCT02250651 Completed - Ocular Hypertension Clinical Trials

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start date: December 15, 2014
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.